We are back in plenary session, virtual edition.

I'm joined by David Russell Germain.

David is, of course, a lymphoma expert already.

He's a hematology oncology fellow Washu, St. Louis.

He's a fast track, MD, Ph.D., too many doctorates, and too much expertise in lymphoma.

David's a pleasure to have you back on the podcast.

It's good to see you.

I also have Aaron Goodman, Papaheim.

He's Popahim.

He's loved by almost 99% of the hematology oncology community.

Aaron, it's great to see you, and don't think about that 1%.

Think about the 99.

Yeah, I could think of one or two people, but thank you.

I'm not as much of a lymphoma expert, but I'm very eager to talk about this subject. Oh, I'm super eager. And I'll take

your 99 any day of the week. I must be at, I think I'm at 72 and dropping rapidly. You're being

generous. I'm being generous. I'm being generous at 72. All right. So we've got three big papers to

talk about. We have politosumab vidotin, which is substituting for Vinka in our chob.

We have Tisagunliclucil and we have AxiCell.

Let's start with Pola.

This is a really good study.

Or is it?

Or is it practice changing?

...